Gatifloxacin: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Gatifloxacin}} | {{Gatifloxacin}} | ||
{{CMG}};{{AE}}{{AK}} | {{CMG}};{{AE}}{{AK}} | ||
'''''For patient information, click <u>[[Gatifloxzcin (patient information)|here]]'''''</u>. | '''''For patient information, click <u>[[Gatifloxzcin (patient information)|here]]'''''</u>. | ||
Revision as of 21:02, 8 January 2014
| Gatifloxacin |
|---|
| GATIFLOXACIN®,ZYMAXID®,ZYMAR® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Clinical Studies |
| Dosage and Administration |
| How Supplied |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
For patient information, click here.
Overview
Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterialenzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin® for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan then withdrawn from the market in 2006. Allergan produces an eye-drop formulation called Zymar®. and Zymaxid .
Category
Fluoroquinolone, fourth generation.
US Brand Names
ZYMAXID®, ZYMAR®, GATIFLOXACIN.
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
References
http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1160b16c-929a-4e85-9c0b-1d8c96a7678b